Amendments to the claims:

This listing of claims replaces all prior versions and listings of claims in the application, and please amend the claims as follows:

1.-25. (Canceled)

26. (Currently amended) A method for producing an immune response against HIV-1 infection in a human comprising the steps of:

(a) administering to the human an immunogenic composition comprising an intranasal or an intramuscular dosage of a recombinant adenovirus comprising an expression cassette containing a promoter, a nucleic acid sequence encoding the HIV-1 gp160 or gp120 polypeptide sequence and a polyadenylation signal sequence; wherein the expression cassette further comprises a coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 or gp120 sequence and before the polyadenylation signal sequence; and

(b) administering to the human one or more intranasal or intramuscular booster dosages of the recombinant adenovirus.

27. (Canceled)

28. (Original) The method of claim 26, wherein the administering one or more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof.

29. (Original) The method of claim 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus.

30. (Canceled)

31. (Original) The method of claim 26, wherein the HIV-1 gp160 sequence is the MN strain gp160 sequence or the LAV strain gp160 sequence.

32. (Original) The method of claim 26, wherein the HIV-1 gp160 sequence is replaced by a sequence encoding the gap-pro region of HIV-1.

33. (Original) The method of claim 26, wherein the intranasal dosage is about 1×10^7 pfu of virus.

34. (Original) The method of claim 26, wherein the intramuscular dosage is about 1×10^7 to 2×10^9 pfu of virus.

35. (Original) The method of claim 26, wherein the intranasal booster dosage is in the range of 1×10^7 to 1×10^8 pfu of virus.

36. (Original) The method of claim 26, wherein the intramuscular booster dosage is about 1×10^{10} to 8×10^{10} pfu of virus.

37. (Original) The method of claim 28, wherein the antigen polypeptide dosage comprises between 200 µg and 0.5 mg of antigen polypeptide.

38. (Original) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene.

39. (Original) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene and a deletion in the E1 gene.

40. (Original) The method of claim 26, wherein the adenovirus comprises a deletion in the E1 gene.

41. (New) A method for producing an immune response against HIV-1 infection in a human comprising the steps of:

(a) administering to the human an immunogenic composition comprising an intranasal or an intramuscular dosage of a recombinant adenovirus comprising an expression cassette

containing a promoter, a nucleic acid sequence encoding the gag-pro region of HIV-1 and a polyadenylation signal sequence; wherein the expression cassette further comprises the coding sequence for the HIV-1 rev gene inserted in frame after the gag-pro region and before the polyadenylation signal sequence; and

(b) administering to the human one or more intranasal or intramuscular booster dosages of the recombinant adenovirus.